Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor

British Journal of Pharmacology

Volumn 121, Issue 1, 1997, Pages 105-117

  Riendeau, D ^a   Percival, M D ^a   Boyce, S ^b   Brideau, C ^a   Charleson, S ^a   Cromlish, W ^a   Ethier, D ^a   Evans, J ^a   Falgueyret, J P ^a   Ford Hutchinson, A W ^a   Gordon, R ^a   Greig, G ^a   Gresser, M ^a   Guay, J ^a   Kargman, S ^a   Leger S ^a   Mancini, J A ^a   O'Neill, G ^a   Ouellet, M ^a   Rodger, I W ^a   Therien M ^a   Wang, Z ^a   Webb, J K ^b   Wong, E ^a   Xu, L ^a   Young, R N ^a   Zamboni, R ^a   Prasit, P ^a   Chan, C C ^a   more..

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

COX 1; COX 2; Cyclo oxygenase; Inflammation; Nonsteroidal anti inflammatory drugs; Prostaglandins

Indexed keywords

1 (4 FLUOROPHENYL) 2 [(4 METHYLSULFONYL)PHENYL]CYCLOPENTENE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5,5 DIMETHYL 3 (3 FLUOROPHENYL) 4 (4 METHYLSULFONYL)PHENYL 2 (5H) FURANONE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ARACHIDONIC ACID; CALCIUM IONOPHORE; CHROMIUM 51; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLOSULIDE; FURANONE DERIVATIVE; INDOMETACIN; LIPOPOLYSACCHARIDE; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; PIROXICAM; PROSTAGLANDIN E2; PROSTANOID; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCHEMISTRY; BLOOD CLOTTING; CHO CELL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISSOCIATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; FECES; FEVER; GASTROINTESTINAL TRACT; GENETIC TRANSFECTION; HYPERALGESIA; MALE; MICROSOME; NONHUMAN; ORAL DRUG ADMINISTRATION; PAW EDEMA; PRIORITY JOURNAL; RAT; SQUIRREL MONKEY; STOICHIOMETRY; THERAPY; THROMBOCYTE;

EID: 8244255009     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701076     Document Type: Article

References (48)

1. ALLISON, M.C., HOWATSON, A.G., TORRANCE, C.J., LEE, F.D. & RUSSELL, R.I. (1992). Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. New Engl. J. Med., 327, 749 - 754.
2. BATTISTINI, B., BOTTING, R. & BAKHLE, Y.S. (1994). COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perspect., 7, 501-512.
3. BERTENSHAW, S.R., TALLEY, J.J., ROGIER, D.J., GRANETO, M.J., ROGERS, R.S., KRAMER, S.W., PENNING, T.D., KOBOLDT, C.M., VEENHUIZEN, A.W., ZHANG, Y. & PERKINS, W.E. (1995). 3,4-Diarylthiophenes are selective COX-2 inhibitors. Bioorg. Med. Chem. Lett., 5, 2919-2922.
4. BRIDEAU, C., KARGMAN, S., LIU, S., DALLOB, A.L., EHRICH, E.W., RODGER, I.W. & CHAN, C.-C. (1996). A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res., 45, 68 - 74.
5. CARR, D.P., HENN, R., GREEN, J.R. & BOTTCHER, I. (1986). Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity of non-steroidal anti-inflammatory drugs in the rat. Agents and Actions, 19, 5/6 374-375.
6. CHAN, C.-C., BOYCE, S., BRIDEAU, C., FORD-HUTCHINSON, A.W., GORDON, R., GUAY, D., HILL, R., LI, C-S., MANCINI, J., PENNETON, M., PRASIT, P., RASORI, R., RIENDEAU, D., ROY, P., TAGARI, P., VICKERS, P., WONG, E. & RODGER, I.W. (1995). Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther., 274, 1531 - 1537.
7. CLARKE, G.D., MACPHERSON, I.S., PETRONE, G. & SPANGLER, R.S. (1994). Antinociceptive effects of non-steroidal anti-inflammatory drugs in a rat model of unilateral hindpaw inflammation. Eur. J. Pharmacol., 257, 103 - 108.
8. COPELAND, R.A., WILLIAMS, J.M., GIANNARAS, J., NURNBERG, S., COVINGTON, M., PINTO, D., PICK, S. & TRZASKOS, J.M. (1994). Mechanism of selective inhibition of the inducible isoform or prostaglandin G/H synthase. Proc. Natl. Acad. Sci. U.S.A., 91, 11202-11206.
9. CROMLISH, W.A., PAYETTE, P., CULP, S.A., OUELLET, M., PERCIVAL, M.D. & KENNEDY, B.P. (1994). High-level expression of active human cyclooxygenase-2 in insect cells. Arch. Biochem. Biophys., 314, 193 - 199.
10. ENGELHARDT, G., HOMMA, D., SCHLEGEL, K., UTZMANN, R. & SCHNITZLER, C. (1995). Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-storoidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm. Res., 44, 423-433.
11. ENGELHARDT, G., BOGEL, R., SCHNITZLER, C. & UTZMANN, R. (1996). Meloxicam: Influence on Arachidonic Acid Metabolism. Part 1. In Vitro findings. Biochem. Pharmacol., 51, 21-28.
12. FUNK, C.D., FUNK, L.B., KENNEDY, M.E., PONG, A.S. & FITZGERALD, G.A. (1991). Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J., 5, 2304 - 2312.
13. FUTAKI, N., HAMASAKA, Y., TAKAHASHI, S., HIGUSHI, S. & OTOMO, S. (1993a). Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J. Pharm. Pharmacol., 45, 753 - 755.
14. FUTAKI, N., YOSHIKAWA, K., HAMASAKA, Y., ARAI, I., HIGUCHI, S., IIZUKA, H. & OTOMO, S. (1993b). NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol., 24, 105 - 110.
15. FUTAKI, N., TAKAHASHI, S., YOKOYAMA, M., ARAI, I., HIGUCHI, S. & OTOMO, S. (1994). NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins, 47, 55 - 59.
16. GANS, K. R., GALBRAITH, W., ROMAN, R.J., HABER, S.B., KERR, J.S., SCHMIDT, W.K., SMITH, C., HEWES, W.E. & ACKERMAN, N.R. (1990). Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther., 254, 180 - 187.
17. GAUTHIER, J.-Y., LEBLANC, Y., BLACK, W.C., CHAN, C.-C., CROMLISH, W.A., GORDON, R., KENNEDY, B.P., LAU, C.K., LEGER, S., WANG, Z., ETHIER, D., GUAY, J., MANCINI, J., RIENDEAU, D., TAGARI, P., VICKERS, P., WONG, E. & PRASIT, P. (1996). Synthesis and evaluation of 2,3-diarylthiophenes as selective COX-2 inhibitors. Part II: Replacing the heterocycle. Bioorg. Med. Chem. Lett., 6, 87-92.
18. GLASER, K., SUNG, M.L., O'NEILL, K., BELFAST, M., HARTMAN, D., CARLSON, R., KREFT, A., KUBRAK, D., HSIAO, C.I., & WEICHMAN, B. (1995). Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur. J. Pharmacol., 281, 107 - 111.
19. GRISWOLD, D.E. & ADAMS, J.I., (1996). Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med. Res. Rev., 16, 181- 206.
20. 2 formation in rat carrageenin-induced pleurisy. Prostaglandins. 51, 19-33.
21. HARRIS, R.C., MCKANNA, J.A., AKAI, Y., JACOBSON, H.R. & DUBOIS, R.N. (1994). Cyclooxygenase-2 is associated with the macula densa or rat kidney and increases with salt restriction. J. Clin. Invest., 94, 2504-2510.
22. HARRIS CALLAN, O., SO, O.-Y. & SWINNEY, D.C. (1996). The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. J. Biol. Chem., 271, 3548-3554.
23. HERSCHMAN, H.R. (1996). Prostaglandin synthase 2. Biochim. Biophys. Acta, 1299, 125 - 140.
24. KARGMAN, S., CHARLESON, S., CARTWRIGHT, M., FRANK, J., RIENDEAU, D., MANCINI. J., EVANS, J. & O'NEILL., G. (1996a). Prostaglandin G/H synthase-1 and -2 in rat, dog, monkey, and human gastrointestinal tract tissues: localization, enzyme activity and inhibition by NSAIDs. Gastroenterlogy, 111, 445-454.
25. KARGMAN, S., WONG, E., GREIG, G.M., FALGUEYRET, J-P., CROMLISH, W., ETHIER, D., YERGEY, J.A., RIENDEAU, D., EVANS, J.F., KENNEDY, B., TAGARI, P., FRANCIS, D.A. & O'NEILL, G.P. (1996b). The mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem. Pharmacol., 52, 1113 - 1125.
26. KLEIN, T., NUSING, R.M., PFEILSCHIFTER, J. & ULLRICH, V. (1994). Selective inhibition of cyclooxygenase 2. Biochem. Pharmcol., 48, 1605-1610.
27. LAINE, L., SLOANE, R., FERRETI, M. & COMINELLI, F. (1995). A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production, Gastrointestinal Endoscopy, 42, 428 - 433.
28. LANDS, W.E.M., LETELLIER, P.R., ROME, L. & VANDERHOEK. J.Y. (1974). Regulation of prostaglandin synthesis. In Prostaglandin Synthase Inhibitors, ed. Robinson, H.J. & Vane, J.R. pp. 1-7, New York: Raven Press.
29. LANGENBACH, R., MORHAM, S.G., TIANO, H.F., LOFTIN, C.D., GHANAYEM, B.I., CHULADA, P.C., MAHLER, J.F., LEE, C.A., GOULDING, E.H., KLUCKMAN, K.D., KIM, H.S. & SMITHIES. O. (1995). Prostaglandin synthase I gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell, 83, 483-492.
30. LEBLANC, Y., GAUTHIER, J.Y., ETHIKR, D., GUAY, J., MANCINI, J., RIENDEAU, D., TAGARI, P., VICKERS, P., WONG, E. & PRASIT, P. (1995). Synthesis and biological evaluation of 2,3-diarylthiophenes as selective COX-2 and COX-1 inhibitors. Bioorg. Med. Chem, Lett., 5, 2123 - 2128.
31. LI, J.J., NORTON, M.B., REINHARD, E.J., ANDERSON, G.D., GREGORY, S.A., ISAKSON, P.C., KOBOLDT, C.M., MASFERRER, J.L., PERKINS, W.E., SEIBERT, K., ZHANG, Y., ZWEIFEL, B.S. & REITZ, D.B. (1996). Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. J. Med. Chem., 39, 1846-1856.
32. MAGNI, E. (1993). The effect of nimesulide on prostanoid formation. Drugs, 46, (suppl. 1): 10 - 14.
33. MASFERRER, J.L., ZWEIFEL, B.S., MANNING, P.T., HAUSER, S.D., LEAHY, K.M., SMITH, W.G., ISAKSON, P.C. & SEIBERT, K. (1994). Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A., 91, 3228 - 3232.
34. MELARANGE, R., GENTRY, C., BLOWER, P.R., TOSELAND, C.D.N. & SPRANGLER, R. (1995). Nabumetone, in contrast to etodolac, lacks gastrointestinal irritancy in the rat: assessment by the inflammatory marker, haptoglobin, and blood loss. Inflammopharmacology, 3, 259 - 270.
35. MURRAY, M.D. & BRATER, D.C. (1993). Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu. Rev. Toxicol., 32, 435 - 465.
36. NOBLE, S. & BALFOUR, J.A. (1996). Meloxicam. Drugs, 51, 424 - 430.
37. OUELLET, M. & PERCIVAL, M.D. (1995). Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem. J., 306, 247 - 251.
38. PERCIVAL, M.D., OUELLET, M., VINCENT, C., YERGEY, J., KENNEDY, B.P. & O'NEILL, G.P. (1994). Purification and characterization of recombinant human cyclooxygenase-2. Arch. Biochem. Biophys., 315, 111 - 118.
39. REITZ, D.B., LI, J.J., NORTON, M.B., REINHARD, E.J., COLLINS, J.T., ANDERSON, G.D., GREGORY, S.A., KOBOLDT, C.M., PERKINS, W.E., SEIBERT, K. & ISAKSON, P.C. (1994). Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J. Med. Chem., 37, 3878 - 3881.
40. ROME, L.H. & LANDS, W.E.M. (1975). Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Natl. Acad. Sci. U.S.A., 72, 4863 - 4865.
41. SEIBERT, K., ZHANG, Y., LEAHY, K., HAUSER, S., MASFERRER, J., PERKINS, W., LEE, L. & ISAKSON, P. (1994). Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. U.S.A., 91, 12013-12017.
42. TAVARES, I.A., BISHAI, P.M. & BENNETT, A. (1995). Activity of nimesulide on constitutive and inducible cyclooxygenases. Drug Res., 45, 1093 - 1095.
43. VANE, J.R. & BOTTING, R.M. (1995). New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res., 44, 1 - 10.
44. VISCO, D., WIDMER, R., SHEN, F., OREVILLO, C., CHRISTEN, A., CHAN, C-C., LEGER, S., PRASIT, P., THERIEN, M., WANG, Z., RODGER, I. & MACINTYRE, E. (1996). The effects of a selective cyclooxygenase-2 (COX-2) inhibitor on adjuvant-induced arthritis in the rat. Prostaglandins, Leukotrienes & Essential Fatty Acids, 55, Suppl. 1, 122.
45. WALLACE, J.L. (1994). Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage-potential for development of gastrointestinal tract safe NSAIDs. Can. J. Physiol. Pharmacol., 72, 1493 - 1498.
46. WIESENBERG-BOTTCHER, I., SCHWEIZER, A., GREEN, J.R., SELTENMEYER, Y. & MULLER, K. (1989). The pharmacological profile of CGP 28238, a highly potent anti-inflammatory compound. Agents Actions, 26, 240 - 242.
47. WILKERSON, W.W., COPELAND, R.A., COVINGTON, M. & TRZASKOS, J.M. (1995). Antiinflammatory 4,5-diaryl pyrroles. 2. Activity as a function of cyclooxygenase-2 inhibition. J. Med. Chem., 38, 3895 - 3901.
48. YOUNG, J.M., PANAH, S., SATCHAWATCHARAPHONG, C. & CHEUNG, P.S. (1996). Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A32187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm. Res., 45, 246 - 253.